Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-NET: Personalized vs Standard 177Lu-DOTATOC in NETs
NCT05387603Phase 3Recruiting
- Sponsor
- Skåne University Hospital
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in Neuroendocrine Neoplasm (NEN) (3 arms), sponsored by Skåne University Hospital. Primary endpoint: Progression-Free Survival. Started Nov 2022; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05387603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387603.